NCNA (NCNA) Stock Price & Analysis
NCNA (NCNA) fell 3.90% to USD 1.97 as of June 10, 2026 at 07:33 UTC, according to Nexqual real-time market data.
NCNA last closed at USD 2.05; the session ranged USD 1.96–2.08 on volume of 55,224 shares. Market capitalization is $8.20M, with a 52-week range of USD 1.33–40 (NCM). Source: Nexqual, June 10, 2026 at 07:33 UTC.
Key Statistics (as of June 10, 2026 at 07:33 UTC)
| Price | USD 1.97 |
|---|---|
| Change | ▼ 3.90% (down) |
| Previous Close | USD 2.05 |
| Open | USD 2.02 |
| Day Range | USD 1.96 – 2.08 |
| 52-Week Range | USD 1.33 – 40 |
| Volume | 55,224 shares |
| Market Cap | $8.20M |
| Exchange | NCM |
Technical Analysis (NCNA)
Nexqual's technical model rates NCNA "SELL" based on 1 bullish and 4 bearish signals across 123 daily candles, as of June 10, 2026 at 07:33 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 48.14 (neutral) |
| vs SMA50 | Below (USD 2.02) |
| MACD | -0 (negative) |
Analyst Ratings (NCNA)
Wall Street analysts rate NCNA "None", per Nexqual as of June 10, 2026 at 07:33 UTC.
| Consensus Rating | None |
|---|
Earnings (NCNA)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-12-31 | USD -64.85 vs est -440 ▲ beat |
| 2024-09-30 | USD -439.6 vs est -790 ▲ beat |
| 2024-06-30 | USD -771.8 vs est -798 ▲ beat |
| 2024-03-31 | USD -823.6 vs est -820 ▼ miss |
Source: Nexqual, June 10, 2026 at 07:33 UTC.
Financials & Fundamentals (NCNA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -193.87% |
| Debt / Equity | 2.78 |
| Current Ratio | 5.6 |
| Total Cash | $24.25M |
| Total Debt | $676,000 |
| Free Cash Flow | $-3.82M |
Source: Nexqual, June 10, 2026 at 07:33 UTC.
Financial Health Score (NCNA)
Nexqual rates NCNA's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 07:33 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $24M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$7M |
| Efficiency | Critical — ROE -194%, ROA -58.3% |
Ownership (NCNA)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +1.05% |
| Shares Outstanding | 4.16M |
| Float | 20.81B |
| Short % of Float | +4.06% |
Source: Nexqual, June 10, 2026 at 07:33 UTC.
Leadership (NCNA)
NCNA is led by Hugh Stephen Griffith (age 57), Founder, CEO & Executive Director, per Nexqual as of June 10, 2026 at 07:33 UTC.
| Founder, CEO & Executive Director | Hugh Stephen Griffith (age 57) |
|---|---|
| Interim Chief Financial Officer | Ian Webster (age 44) |
| Chief Operating Officer | Theresa Bruce (age 60) |
| Senior Vice President of Regulatory Affairs | Stuart Grant |
Major Backers & Investors (NCNA)
Notable institutional backers of NCNA include Glass Jacobson Investment Advisors LLC, Citadel, Virtu Financial LLC, according to Nexqual as of June 10, 2026 at 07:33 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Glass Jacobson Investment Advisors LLC | 0.36% |
| Citadel | 0.33% |
| Virtu Financial LLC | 0.32% |
| Jane Street Group, LLC | 0.25% |
Source: Nexqual, June 10, 2026 at 07:33 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MBIO | Mustang Bio, Inc. | USD 0.74 | ▲ 10.75% |
| GLMD | Galmed Pharmaceuticals Ltd. | USD 0.52 | ▼ 25.03% |
| TLPH | Talphera, Inc. | USD 0.82 | ▲ 4.56% |
| ADIL | Adial Pharmaceuticals, Inc | USD 2.13 | ▼ 3.62% |
| PHIO | Phio Pharmaceuticals Corp. | USD 1.08 | ▲ 1.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:33 UTC. This page is informational and not investment advice.